A phase Ib/II trial enrolled a small number of patients with HER2 negative breast cancer to investigate the safety and efficacy of nab paclitaxel + alpelisib; the results showed promising efficacy, especially in PI3K mutated tumours. This evidence concerns the gene ERBB2 and breast cancer.